Healthcare / Drug Manufacturers - Specialty & GenericBSE
$367.80
+8.35 (+2.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-24.4M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
19.2x
↓EV/EBITDA
10.9x
↓ROE
15.3%
↑Gross Margin
27.1%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+9.1%
FCF CAGR
—
FCF margin
-2.5%
FCF / Net income
-0.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $959.5M · net income $108.1M · FCF $-24.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $959.5M | $959.5M | $665.1M | $848.4M | $738.4M |
| Net Income | $108.1M | $108.1M | $92.7M | $98.7M | $82.0M |
| EBITDA | $161.2M | $161.2M | $134.5M | $140.1M | $117.9M |
| EPS | — | — | 16.11 | 17.14 | 14.25 |
| Gross Margin | 27.1% | 27.1% | 37.8% | 29.0% | 32.7% |
| Operating Margin | 13.6% | 13.6% | 16.1% | 14.0% | 14.1% |
| Net Margin | 11.3% | 11.3% | 13.9% | 11.6% | 11.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.14 | 0.09 |
| Current Ratio | 4.00 | 4.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-24.4M | $-24.4M | $145.6M | $-37.6M | $62.9M |
| Returns | |||||
| ROE | 15.3% | 15.3% | 13.5% | 15.9% | 15.0% |
| Valuation | |||||
| P/E | 19.16 | 19.16 | 16.87 | 17.70 | 8.43 |
| EV/EBITDA | 10.90 | 10.90 | 9.43 | 11.33 | 4.12 |
| P/B | 3.00 | 3.00 | 2.28 | 2.81 | 1.26 |
| Growth & Yield | |||||
| Revenue Growth | 44.3% | 44.3% | -21.6% | 14.9% | — |
| EPS Growth | — | — | -6.0% | 20.3% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+41.3%
Start / end P/E
n/dx → n/dx
EPS bridge
16.11 → n/d
Residual
+40.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.